Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.
N Engl J Med. 2013.
PMID: 23738544
Free article.
Clinical Trial.